logo-loader

Summit Therapeutics completes dosing of ezutromid in PhaseOut DMD clinical trial

Published: 07:49 19 Apr 2018 EDT

Small boy with pets
DMD is a muscle disease that affects boys and young men

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) said ezutromid dosing in patients with Duchenne muscular dystrophy (DMD) for the full 48-week PhaseOut DMD clinical trial has been completed.

Top-line results from the full trial continue to be expected in the third quarter of 2018, the company said in a statement.

WATCH: Summit Therapeutics accelerating preparatory activities for next DMD study

Summit's utrophin modulator, ezutromid, is a potential breakthrough treatment for sufferers of DMD, a fatal wasting disease that affects boys and young men.

Interim data from the trial has already revealed a statistically significant reduction in muscle damage and inflammation in patients after just 24-weeks.

READ: Summit Therapeutics shares jump on initial positive results of clinical trial for DMD​

"We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In the full trial results, we aim to see continued utrophin modulation and sustained changes in magnetic resonance parameters,” said Dr David Roblin, the chief medical officer and president of research & development at Summit.

"These results, if positive, could form the basis of a regulatory filing of ezutromid, bringing this universal treatment to patients more rapidly," he added.

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 41 minutes ago